IP Library › Granted Patent US 9,044,418
Granted Patent B2
US 9,044,418 · App. 14/512,292 · Granted Jun 2, 2015

Treatment for depression and other mental conditions with synthetic isotope-modified lithium

Inventor: Matthew P. A. Fisher (Santa Barbara, CA)
A61K33/00A61K8/19A61K33/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,044,418
App. No.
14/512,292
Granted
Jun 2, 2015
Kind
B2
Abstract

Treating mental illness by administering synthetic isotope-modified lithium compounds: (i) with the lithium-6 isotope making up at least 95% of the total number of lithium atoms in the compound to treat depression and other mental conditions with reduced alertness levels, (ii) with the lithium-7 isotope making up at least 95% of the total number of lithium atoms in the compound to treat mania and bipolar disorder and other mental illnesses which respond to lithium compounds with natural isotope abundance levels, (iii) with the lithium-6 isotope ranging from 10% to 95% of the total number of lithium atoms in the compound individually tailored to treat patients with a broad variety of mental disorders, including those in (i) and (ii) above.

Claims (19)

1. A method for treating mental conditions, comprising administering a synthetic isotope-modified lithium-compound containing lithium-6 isotopes in an amount of at least 95% of a total number of lithium atoms in the compound, at dosages of about 100 mg/day to 1500 mg/day, whereby a symptom of the mental condition is alleviated.

2. The method of claim 1 , wherein the mental condition is selected from the group consisting of depression, attention deficit disorder, dementia, reduced alertness, amnesia, and poor memory recall.

3. The method of claim 2 , wherein the mental condition is depression.

4. The method of claim 3 , wherein the dosages range from 100 mg/day to less than 300 mg/day.

5. The method of claim 4 , wherein the compound is selected from the group consisting of lithium carbonate, lithium citrate, lithium orotate, lithium-chloride.

6. The method of claim 5 , wherein the compound is lithium carbonate.

7. A method of treating mental conditions comprising administering a synthetic isotope-modified lithium-compound containing lithium-7 isotopes in an amount of at least 95% of a total number of lithium atoms in the compound, at dosages of 200 mg/day to 1200 mg/day, whereby a symptom of the mental condition is alleviated.

8. The method of claim 7 , wherein the mental condition is selected from the group consisting of mania and bipolar disorder.

9. The method of claim 8 , wherein the mental condition is mania.

10. The method of claim 9 , wherein the lithium carbonate is administered at dosages of 200 mg/day to less than 300 mg/day.

11. The method of claim 10 , wherein the compound is selected from the group consisting of lithium carbonate, lithium citrate, lithium orotate, and lithium-chloride.

12. The method of claim 11 , wherein the compound is lithium carbonate.

13. A method of treating mental conditions by administering a synthetic isotope-modified lithium-compound containing lithium-6 isotopes in an amount ranging from 10% to 95% of a total number of lithium atoms in the compound, wherein the compound is administered at dosages ranging from 100 mg/day to 1500 mg/day, whereby a symptom of the mental condition is alleviated.

14. The method of claim 13 , wherein the lithium-6 isotopes are present in an amount between 25% and 15% of the total number of lithium atoms in the compound.

15. The method of claim 13 , wherein the lithium-6 isotopes are present in an amount between 35% and 75% of the total number of lithium atoms in the compound.

16. The method of claim 13 , wherein the lithium-6 isotopes are present in an amount between 45% and 65% of the total number of lithium atoms in the compound.

17. The method of claim 13 , wherein the dosages range from 100 mg/day to less than 300 mg/day.

18. The method of claim 13 , wherein the mental condition is selected from the group consisting of depression, attention deficit disorder, dementia, reduced alertness, amnesia, poor memory recall, mania, and bipolar disorder.

19. The method of claim 18 , wherein the mental condition is depression.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2020
From: INFINITE STATE INC.
To: FISHER, MATTHEW P. A.
Reel/Frame 052181/0942 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2019
From: FISHER, MATTHEW P. A.
To: INFINITE STATE INC.
Reel/Frame 050962/0819 →
Continuity (2)
Provisional Application 61890103 · Oct 11, 2013
Related Publication 20150104528A1 · Apr 16, 2015